JUNEL FE 1/20
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNEL FE 1/20 (JUNEL FE 1/20).
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
| Metabolism | Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized by reduction and conjugation (glucuronidation and sulfation). |
| Excretion | Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal. |
| Half-life | Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days. |
| Protein binding | Ethinyl estradiol: ~97% bound to albumin; norethindrone: ~61% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Ethinyl estradiol: 2.0-4.0 L/kg; norethindrone: 3.0-4.5 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: Ethinyl estradiol ~45% (due to first-pass metabolism); norethindrone ~64%. |
| Onset of Action | Oral: Contraceptive effect requires 7 days of continuous dosing; therapeutic effects on menstrual cycle begin within first cycle. |
| Duration of Action | 24 hours (daily dosing required); contraceptive protection persists as long as taken daily without missed doses. |
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use contraindicated in patients with renal disease or renal impairment if it worsens or is associated with hyperkalemia. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) or active liver disease. No dose adjustment applicable. |
| Pediatric use | Safety and efficacy not established in pediatric patients. Not indicated for use before menarche. |
| Geriatric use | Not indicated for use in postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke or have other risk factors. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUNEL FE 1/20 (JUNEL FE 1/20).
| Breastfeeding | Small amounts of ethinyl estradiol and norethindrone (the active components) are excreted into breast milk. The M/P ratio is approximately 0.1-0.3 for ethinyl estradiol and 0.5-1.0 for norethindrone. Use is generally not recommended during breastfeeding as it may reduce milk production and quality. If used, monitor infant for jaundice and growth. |
| Teratogenic Risk | Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal genital tract abnormalities (e.g., hypospadias, feminization of male fetuses). |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes per day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
["Thrombophlebitis, thromboembolic disorders, or history of these conditions","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Carcinoma of the endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component","Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations"]
| Precautions | ["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Hypertension","Carbohydrate and lipid metabolic effects","Headache","Bleeding irregularities","Depression","Ocular lesions (e.g., retinal thrombosis)","Carcinoma of the breast and reproductive organs","Use in pregnancy (discontinue if pregnancy occurs)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, liver function, and signs of thromboembolism. Fetal monitoring via ultrasound for growth and development if inadvertent exposure. |
| Fertility Effects | Normal ovarian function is suppressed during use, but fertility returns promptly after discontinuation. No evidence of permanent impairment of fertility. |